The use of β-CDs can help to overcome one of the main challenges in drug delivery: guaranteeing the bioavailability of APIs, especially when they are poorly soluble and/or with a limited gastrointestinal permeability.
To improve aqueous solubility and thus the therapeutic effectiveness of such compounds, a number of formulation strategies have already been largely tested. It is a big challenge to find the right solubilization tool for these active ingredients.